Background
==========

*Acinetobacter* species have emerged as important pathogens causing nosocomial infections \[[@B1]\]. Carbapenem resistant *Acinetobacter* spp. are now increasingly encountered worldwide \[[@B2],[@B3]\], especially in the Asia-Pacific region \[[@B4]-[@B6]\]. The three most clinically relevant *Acinetobacter* species, *Acinetobacter baumannii*, *Acinetobacter nosocomialis* (formerly *Acinetobacter* genomic species 13TU), and *Acinetobacter pittii* (formerly *Acinetobacter* genomic species 3), cannot be differentiated by phenotypic tests used in clinical microbiological laboratories and are grouped as the *A*. *baumannii* (Ab) group \[[@B1]\]. Though the prevalence of *Acinetobacter* species in the Ab group vary in different geographic areas and institutions, *A*. *baumannii* and *A*.*nosocomialis* are commonly isolated clinical *Acinetobacter* species worldwide \[[@B7]-[@B12]\] and accounting for more than 80% of clinical infections caused by the Ab group in Taiwan \[[@B10],[@B13],[@B14]\].

Compared to bacteremia caused by *A*. *nosocomialis*, bacteremia caused by *A*. *baumannii* is associated with worse clinical outcomes \[[@B10],[@B12],[@B13],[@B15]\]. The higher mortality in patients with *A*. *baumannii* might be attributed to a higher pathogenicity of *A*. *baumannii*\[[@B10],[@B15]\]. However, it is unknown whether the more severe clinical outcomes of *A*. *baumannii* bacteremia compared to *A*. *nosocomialis* bacteremia will be the same if both the pathogens are carbapenem resistant, as it has been shown that the virulence of *A*. *baumannii* resistant to certain drugs is impaired \[[@B16],[@B17]\]. In this study, we aim to compare the clinical characteristics, antimicrobial susceptibilities of the bacterial isolates, and especially the clinical outcomes of patients with bacteremia caused by carbapenem resistant *A*. *baumannii* (CRAB) and *A*. *nosocomialis* (CRAN).

Methods
=======

Study population
----------------

The study was conducted at the Taipei Veterans General Hospital (T-VGH) during a nine-year period from January 2000 to December 2008. T-VGH is a 2900-bed tertiary-care teaching hospital located in Taipei, Taiwan. Data analyses were performed at the Tri-Service General Hospital (TSGH), National Defense Medical Center in Taipei, Taiwan.

Charts were reviewed from all patients with at least one positive blood culture for *A*. *baumannii* or *A*. *nosocomialis* who had symptoms and signs of infection. Only the first blood culture from patients with two or more positive blood cultures was included. The source of infection was determined as recommended in Centers of Disease Control guidelines \[[@B18],[@B19]\]. Bacteremia cases without a definite identified source were defined as primary bacteremia. Patients under 18 years of age and those with incomplete medical records were excluded. The protocol was approved by the T-VGH and TSGH Institutional Review Board (approval number: 2011-10-012IC and 2-101-05-074, respectively) with a waiver for informed consent.

Microbiological studies
-----------------------

The presumptive identification of the isolates to the level of the Ab group was performed with the API ID 32 GN system (bioMérieux, Marcy l'Etoile, France) or Vitek 2 system (bioMérieux, Marcy l'Etoile, France). A multiplex-PCR method was used to identify *A*. *baumannii* to the genomic species level \[[@B20]\]. Isolates identified as non-*A*. *baumannii* species of *Acinetobacter* were identified to the genomic species level by 16S--23S ribosomal DNA intergenic spacer sequence analysis \[[@B21]\]. Antimicrobial susceptibilities were determined by the agar dilution method according to the Clinical Laboratory Standards Institute (CLSI) \[[@B22]\]. Multidrug resistance was defined as resistance to three or more of the following classes of antimicrobial agents: anti-pseudomonal cephalosporins, anti-pseudomonal carbapenems, ampicillin/sulbactam, fluoroquinolones, and aminoglycosides \[[@B1]\].

Molecular typing
----------------

The clonal relationships of the clinical isolates were determined by pulsed-field gel electrophoresis (PFGE) \[[@B23]\]. Twenty randomly selected isolates from each *Acinetobacter* species were performed. PFGE of *Apa*I-digested genomic DNA was performed using the Bio-Rad CHEF-Mapper apparatus (Bio-Rad Laboratories, Hercules, CA, USA). Cluster analysis was performed using BioNumerics version 5.0 (Applied Maths, Sint-Martens-Latem, Belgium) and the unweighted pair-group method with arithmetic averages (UPGMA). The Dice correlation coefficient was used with a tolerance of 1% in order to analyze any similarities between banding patterns. Isolates showing more than three DNA fragment differences and a similarity of \<80% following dendrogram analysis were considered to represent different pulsotypes.

Data collection
---------------

Medical records were reviewed to extract clinical information, including demographic characteristics, underlying diseases, duration of stay in an intensive care unit (ICU), hospital stay, time of receipt, dose and route of administration of individual antimicrobials, and the presence of a ventilator, central venous catheters, a nasogastric tube, or a foley catheter at the time of onset of bacteremia. Immunosuppressive therapy was defined as receipt of cytotoxic agents within 6 weeks, corticosteroids at a dosage equivalent to or higher than 10 mg of prednisolone daily for more than 5 days within 4 weeks, or other immunosuppressive agents within 2 weeks prior to the onset of bacteremia. Neutropenia was defined as an absolute neutrophil count \<0.5×10^9^ neutrophils/L. Recent surgery was defined as operations performed within 4 weeks prior to the onset of bacteremia. Chronic kidney disease was defined as an estimated glomerular filtration rate \<60 mL/min/1.73 m^2^. Shock was defined as hypotension (systolic blood pressure \[SBP\] \<90 mmHg, mean arterial pressure \<70mmHg, or a SBP decrease \>40 mmHg) with evidence of end organ dysfunction \[[@B24]\]. Polymicrobial bacteremia was defined as isolation of one or more microorganisms other than *A*. *baumannii* or *A*. *nosocomialis* from blood during the same bacteremic episode. The severity of illness was evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score \[[@B25]\] within 24 hours prior to bacteremia onset.

Appropriate antimicrobial therapy was defined as administration of at least one antimicrobial agent, to which the causative pathogen was susceptible, within 48 hours after the onset of bacteremia, with an approved route and dosage for end organ(s) function. Antimicrobial therapy that did not meet this definition was considered inappropriate. Monotherapy with an aminoglycoside was not considered an appropriate therapy. The primary outcome measure was all-cause 14-day mortality following the onset of CRAB or CRAN bacteremia.

Statistical analysis
--------------------

To assess differences, the chi-square test with Yate's correction or Fisher's exact test was used to compare the discrete variables, while the Student's *t*-test or Mann--Whitney rank sum test was used to analyze continuous variables. Logistic regression models were used to explore independent risk factors for 14-day mortality. Univariate analyses were performed separately for each of the risk factor variables to ascertain the odds ratio (OR) and 95% confidence interval (CI). All biologically plausible variables with a *p* value of ≤0.10 in the univariate analysis exhibited by at least 10% of the patients were considered for inclusion in the logistic regression model for the multivariate analysis. A backward selection process was utilized. Time to mortality was analyzed using Kaplan-Meier survival analysis and long-rank test. A *p* value \<0.05 was considered statistically significant. All the analyses were processed with Statistical Package for the Social Sciences (SPSS) software version 18.0 (SPSS, Chicago, IL, USA).

Results
=======

During the study period, 801 patients were found to have at least one episode of Ab group bacteremia. Among them, 185 (23.1%) patients with polymicrobial bacteremia were excluded from the study. Following genomic species analysis, 259 (42.0%) and 294 (47.7%) patients were identified as having bacteremia caused by *A*. *baumannii* and *A*. *nosocomialis*, respectively. The final population that met the entry criteria for this study consisted of 71 patients with CRAB bacteremia and 64 patients with CRAN bacteremia. A total of 43 patients were excluded due to young age (13 patients \<18 years) and incomplete medical records (30 patients).

Among the 20 randomly selected CRAB and CRAN isolates, the analysis of PFGE showed that there were 7 and 14 pulsotypes, respectively (data not shown).

The demographic and clinical characteristics of the patients included in the study are summarized in Table [1](#T1){ref-type="table"}. The most common source of CRAB and CRAN bacteremia was the respiratory tract (66.2% and 70.3%, respectively). Patients with CRAB had hematologic malignancies more frequently than those with CRAN (12.7% vs. 1.6%, *p* = 0.019). Though APACHE II scores at the onset of bacteremia were similar in both groups, shock was more frequently present in patients with CRAB.

###### 

**Demographic and clinical characteristics of patients with bacteremia caused by carbapenem resistant*Acinetobacter baumannii*and carbapenem resistant*Acinetobacter nosocomialis***\*

  **Demographic or characteristic**           ***A. baumannii*(n=71)**   ***A. nosocomialis*(n=64)**   ***p*value**
  ------------------------------------------ -------------------------- ----------------------------- --------------
  Age in years                                     75(61.0--82.0)              76(62.0--81.0)              0.78
  Gender, male                                        54(76.1)                    46(71.9)                 0.7
  Acquired in ICU                                     60(84.5)                    54(84.4)                  1
  Days of hospitalization prior to culture        22.5(9.5--39.5)               25(8.0--34.0)              0.26
  Source                                                                                                     
    Respiratory tract                                 47(66.2)                    45(70.3)                 0.71
    Intravenous device                                 4(5.6)                      7(10.9)                 0.35
    Intra-abdomen                                      6(8.5)                      3(4.7)                  0.5
    Wound                                              2(2.8)                      1(1.6)                   1
    Primary bacteremia                                12(16.9)                     8(12.5)                 0.32
  Comorbidity                                                                                                
    Coronary artery disease                            7(9.9)                     11(17.2)                 0.31
    Congestive heart failure                           5(7.0)                     11(15.6)                 0.11
    Cerebral vascular disease                         13(18.3)                    17(26.6)                 0.3
    Hypertension                                      22(31.0)                    25(39.1)                 0.37
    COPD                                              14(19.7)                    20(31.2)                 0.17
    Alcoholism                                         7(9.9)                      1(1.6)                  0.07
    Liver cirrhosis                                    3(4.2)                      3(4.7)                   1
    Diabetes mellitus                                 20(28.2)                    22(34.4)                 0.46
    Collagen vascular disease                          4(5.6)                      4(6.2)                   1
    Usage of immunosuppressants                       23(32.4)                    15(23.4)                 0.26
    Neutropenia                                        2(2.8)                      1(1.6)                   1
    Malignancy                                        27(38.0)                    24(37.5)                  1
      Hematologic malignancy                          9(12.7)                      1(1.6)                 0.019
      Solid malignancy                                20(28.2)                    23(35.9)                 0.36
    Recent surgery                                    26(36.6)                    29(45.3)                 0.38
    Trauma                                             2(2.8)                      2(3.1)                   1
  Procedure†                                                                                                 
    Abdominal drain                                    7(9.9)                      9(14.1)                 0.6
    Central venous catheter                           49(69.0)                    47(73.4)                 0.7
    Foley catheter                                    53(74.6)                    44(48.8)                 0.57
    Hemodialysis                                      9(12.7)                      8(12.5)                  1
    Thoracic drain                                     1(1.4)                      4(6.2)                  0.19
    Total parental nutrition                          9(12.7)                      7(10.9)                 0.8
    Endotracheal tube or tracheostomy                 53(74.6)                    53(82.8)                 0.3
    Ventilator                                        49(69.0)                    45(70.3)                  1
    Arterial line                                     22(31.0)                    12(18.8)                 0.12
    Nasogastric tube                                  61(85.9)                    51(79.7)                 0.37
  APACHE II score†                                 26(19.0--34.0)              26(18.3--31.8)              0.1
  Shock                                               29(40.8)                    10(15.6)                0.003
  Appropriate antimicrobial therapy                   9(12.7)                     22(34.4)                0.004
  Mortality                                           43(60.6)                    21(32.8)                0.002
   14-day mortality                                   29(40.8)                     9(14.1)                0.001
   28-day mortality                                   34(47.9)                    13(20.3)                0.001
   Time to mortality, day                           7(2.0--26.0)                21(9.5--68.5)             0.022

\*Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables. †Within 24 hours prior to bacteremia onset. *APACHE II* Acute Physiologic and Chronic Health Evaluation II, *COPD* chronic obstructive pulmonary disease, *ICU* intensive care units.

The antimicrobial susceptibilities of the clinical isolates of CRAB and CRAN are shown in Table [2](#T2){ref-type="table"}. CRAB exhibited significantly higher rates of resistance to all antimicrobials tested, except colistin and piperacillin/tazobactam. Only one *A*. *baumannii* isolate was resistant to colistin (1.4%), while in contrast, 45.3% (29/64) of the *A*. *nosocomialis* isolates were resistant to colistin (*p*\<0.001). Clinical isolates of CRAB exhibited multidrug resistance more frequently than CRAN (100% vs. 75%, *p*\<0.001). Patients with CRAB more frequently received inappropriate antimicrobial therapies than those with CRAN (Table [1](#T1){ref-type="table"}).

###### 

**Comparison of antimicrobial susceptibilities of clinical isolates of carbapenem resistant*Acinetobacter baumannii*and carbapenem resistant*Acinetobacter nosocomialis***

                             **Resistance, n (%)**             
  ------------------------- ----------------------- ---------- ---------
  Amikacin                         68(95.8)          30(46.9)   \<0.001
  Gentamicin                       68(95.8)          54(84.4)    0.038
  Ceftazidime                      69(97.2)          14(21.9)   \<0.001
  Cefepime or cefpirome            49(69.0)          13(20.3)   \<0.001
  Ampicillin/sulbactam             43(60.6)          27(42.2)    0.039
  Piperacillin/tazobactam          56(78.9)          42(65.6)    0.12
  Ciprofloxacin                    69(97.2)           4(6.2)    \<0.001
  Colistin                          1(1.4)           29(45.3)   \<0.001
  Tigecycline                       6(8.2)             0(0)      0.03

The antimicrobials used, the APACHE II score, appropriateness of antimicrobial use, and patient outcomes are shown in Table [3](#T3){ref-type="table"}. Due to the limited number of cases, differences in illness severity, and appropriateness of therapy in each therapy group, it was difficult to evaluate the effect of different antimicrobial therapies on patients with CRAB and CRAN bacteremia. Overall, the mortality rate of CRAB was higher than CRAN in different antimicrobial therapy groups. For example, in the carbapenem therapy groups, in which the illness of severity was comparable between both groups, the 14-day mortality rates in CRAB and CRAN groups were 41.2% vs. 14.3%, respectively. In the sulbactam therapy group, although the illness severity was lower in the CRAB group, the 14-day mortality rate was still higher (45.5 vs. 0%).

###### 

**Antimicrobials used for the patients with carbapenem resistant*Acinetobacter baumannii*and*Acinetobacter nosocomialis*bacteremia**\*

  **Main agents used**                    **No. of patients**   **APACHE II score**   **No. (%) of patients**  
  -------------------------------------- --------------------- --------------------- ------------------------- ---------
  Anti-pseudomonal penicillins^a^                                                                              
  CRAB                                            12             31.5(22.8--39.0)             2(16.7)           6(50.0)
  CRAN                                             8              24(19.0--33.0)              7(87.5)           2(25.0)
  Anti-pseudomonal cephalosporins^b^                                                                           
  CRAB                                            14              26(22.8--34.0)              2(14.3)           4(28.6)
  CRAN                                            10              26(19.3--30.0)              7(70.0)           1(10.0)
  Anti-pseudomonal fluoroquinolones^c^                                                                         
  CRAB                                             5              30(21.0--36.0)              1(20.0)           2(40.0)
  CRAN                                             2             37.5(37.0--38.0)            2(100.0)            0(0)
  Anti-pseudomonal carbapenems^d^                                                                              
  CRAB                                            17              32(24.0--38.5)               0(0)             7(41.2)
  CRAN                                            14             30.5(23.0--33.3)              0(0)             2(14.3)
  Ampicillin/sulbactam or sulbactam                                                                            
  CRAB                                            11              17(15.0--33.0)              4(36.4)           5(45.5)
  CRAN                                             8              24(18.0--27.5)              3(37.5)            0(0)
  Non-antipseudomonal β-lactamases^e^                                                                          
  CRAB                                             6             17.5(15.3--25.3)              0(0)             1(16.7)
  CRAN                                             9              18(15.5--24.0)              3(33.3)           1(11.1)
  Miscellaneous                                                                                                
  CRAB                                             6              25(17.8--32.0)               0(0)             2(33.3)
  CRAN                                            13              27(16.0--35.5)               0(0)             3(23.1)

\*Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables. ^a^Including piperacillin, piperacillin/tazobactam, and ticarcillin/clavulanate. ^b^Including cefoperazone, ceftazidime, cefepime, and cefpirome. ^c^Including ciprofloxacin and levofloxacin. ^d^Including imipenem and meropenem. ^e^Including penicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole, and flomoxef. *APACHE II* Acute Physiologic and Chronic Health Evaluation II, *CRAB* carbapenem resistant *A*. *baumannii*, *CRAN* carbapenem resistant *A*. *nosocomialis*.

The mortality rates by 14 and 28 days after bacteremia onset were significantly higher in patients with bacteremia caused by CRAB than CRAN (*p* = 0.001). The 14-day mortality for CRAB was 40.8% (29/71) compared with 14.1% (9/64) for CRAN. The average time from admission to death was significantly shorter in CRAB than CRAN(16.7 days vs. 39.4 days, *p* = 0.022). Kaplan-Meier survival curves reflected the early occurrence of death within a few days following bacteremia for patients infected with CRAB. This was followed by higher rates of death in the CRAB group than the CRAN group (*p* = 0.001, by log-rank test) (Figure [1](#F1){ref-type="fig"}).

![**Kaplan**-**Meier survival curves for patients with carbapenem resistant*Acinetobacter baumannii*bacteremia and carbapenem resistant*Acinetobacter nosocomialis*bacteremia.**](1471-2334-13-311-1){#F1}

Factors associated with 14-day mortality are summarized in Table [4](#T4){ref-type="table"}. Bacteremia with CRAB, higher APACHE II score, use of immunosuppressants and shock were univariable risk factors for mortality. Following logistic regression analysis, *A*. *baumannii* itself was found to be an independent risk factor for mortality among all patients (odds ratio = 4.003; 95% confidence interval = 1.566-10.231; *p* = 0.004). The usage of immunosuppressants was also an independent risk factor for mortality.

###### 

**Factors associated with 14**-**day mortality in patients with carbapenem resistant*Acinetobacter baumannii*and*Acinetobacter nosocomialis*bacteremia**

  **Demographic and characteristics**    **Univariate analysis**  **Multivariate analysis**                          
  ------------------------------------- ------------------------- --------------------------- ---------------------- -------
  *A*. *baumannii*                         4.220(1.806--9.861)    0.001                        4.003(1.566--10.231)  0.004
  APACHE II score\*                        1.165(1.098--1.237)    \<0.001                                             
    Score ≤25                              1.127(0.965--1.317)    0.131                                               
    Score \>25                             1.062(0.986--1.144)    0.113                                               
    Score ≤35                              1.086(1.012--1.166)    0.022                                               
    Score \>35                             1.056(0.895--1.247)    0.113                                               
  Cerebral vascular disease                0.222(0.063--0.783)    0.019                        0.194(0.048--0.789)   0.022
  Usage of immunosuppressants              4.105(1.827--9.227)    0.001                        3.921(1.516--10.143)  0.005
  Appropriate antimicrobial therapy        0.381(0.144--1.004)    0.051                                               
  Recent surgery                           0.190(0.073--0.494)    0.001                        0.222(0.079--0.628)   0.005
  Shock                                    2.760(1.244--6.122)    0.013                                               

\*Every one increase in APACHE II score is accompanied by an increase of 1.165 in the odds ratio. *APACHE II* Acute Physiologic and Chronic Health Evaluation II, *CI* Confidence interval.

Discussion
==========

This study clearly demonstrates significant differences in the risk factors, antimicrobial resistances, and especially clinical outcomes between bacteremia caused by CRAB and CRAN. Patients infected with CRAB were more likely to have hematologic malignancies and a greater frequency of shock. Even though both pathogens were carbapenem resistant, CRAB exhibited resistance to more antimicrobial agents. CRAB bacteremia was also associated with more frequent instances of inappropriate antimicrobial use, as well as more rapid and higher mortality rates. Among the patients with CRAB and CRAN bacteremia, acquisition of CRAB was found to be an independent factor for 14-day mortality.

Compared with CRAN, CRAB had higher resistance rates toward most commonly used antimicrobial agents, and all CRAB isolates were multidrug resistant. This resistance is responsible for the increased chance of receiving an inappropriate antimicrobial therapy in patients infected with these microorganisms. On the contrary, there were still some therapeutic options available for the treatment of CRAN bloodstream infections. A higher rate of colistin resistance in *A*. *nosocomialis* than *A*. *baumannii* was also observed in previous reports \[[@B14],[@B26],[@B27]\], where the resistance of colistin in *A*. *nosocomialis* was about 20%. In this study, it was even higher in CRAN isolates (45.3%).

The higher mortality of patients infected with CRAB compared to CRAN may be attributed to unfavorable underlying diseases, an increased likelihood of inappropriate antimicrobial therapy in the former group, and possibly higher pathogenicity of *A*. *baumannii*\[[@B10],[@B13]\]. According to our findings, there were more shock episodes in patients with CRAB than with CRAN of similar disease severity. Furthermore, CRAB was identified as an independent risk factor for mortality after adjustment for other risk factors for mortality, including underlying diseases, severity of illness, and appropriateness of antimicrobial therapy. This result indicates a possible higher pathogenicity of CRAB compared to CRAN. Because of the diversity of the clonality of CRAB and CRAN isolates, we believe that the result is due to species but not strain effect. Genomic species identification is therefore important to better delineate the role of different species of carbapenem resistant *Acinetobacters*\[[@B21],[@B28]\].

The prevalence of *Acinetobacter* species in the Ab group can vary in different geographic areas and institutions. For example, *A*. *pittii* was found to be the predominant species accounting for clinical infections in Germany during 2005-2009 \[[@B11]\]. Although *A*. *baumannii* and *A*. *nosocomialis* account for more than 80% of clinical infections caused by the Ab group, their ratio differs among centers in Taiwan \[[@B10],[@B13]-[@B15]\]. Three centers demonstrated a \>2:1 relative ratio of *A*. *baumannii* to *A*. *nosocomialis*\[[@B10],[@B13],[@B15]\], however, the ratio has consistently been around 1:1 in our center in recent years \[[@B26],[@B29]\].

This study is subject to several limitations regularly found in retrospective studies. Several confounding factors, especially the antimicrobials used during the whole treatment course, could not be well controlled in both groups. However, it is not likely that certain antimicrobial regimens that might affect clinical outcomes were used more often in either group as the primary physicians were unaware of the genomic species.

Conclusions
===========

CRAB and CRAN bacteremia are different in clinical characteristics, antimicrobial susceptibilities, and mortality rates. Genomic species identification should be performed in the study of carbapenem resistant *Acinetobacters* to better delineate the role of different species.
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